Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

21.90 +0.92 (+4.39%)
Streaming Delayed Price Updated: 9:57 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 260,361
Open 21.62
Bid (Size) 21.86 (100)
Ask (Size) 21.94 (200)
Prev. Close 20.98
Today's Range 21.56 - 22.20
52wk Range 20.21 - 45.30
Shares Outstanding 308,456,852
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares ↗
Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline. 
Via The Motley Fool
News headline image
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+1.8%
+1.8%
1 Month
-16.2%
-16.2%
3 Month
-30.3%
-30.3%
6 Month
-41.6%
-41.6%
1 Year
-36.9%
-36.9%

More News

Read More
News headline image
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
What to Expect from Legend Biotech's Earnings ↗
Via Benzinga
News headline image
How Do Investors Really Feel About Legend Biotech? ↗
Via Benzinga
News headline image
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Considering Second Listing Outside US: Report ↗
Via Stocktwits
News headline image
How Do Investors Really Feel About Legend Biotech? ↗
Via Benzinga
News headline image
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Inside the Fintech Platform Winning Over a New Generation of Investors in Asia ↗
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
XP’s New Backer Sees Opportunity in Brazil’s Next Financial Chapter ↗
Via The Motley Fool
News headline image
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
AMD To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Friday ↗
Via Benzinga
News headline image
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗
Via Stocktwits
Topics Government World Trade
News headline image
Expert Outlook: Legend Biotech Through The Eyes Of 6 Analysts ↗
Via Benzinga
News headline image
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
The Analyst Verdict: Legend Biotech In The Eyes Of 5 Experts ↗
Via Benzinga
News headline image
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Via MarketMinute
Topics Economy Stocks
News headline image
Legend Biotech Corp. (NASDAQ:LEGN) Reports Mixed Q2 2025 Earnings with Revenue Beat and EPS Miss Amid Strong CARVYKTI Sales ↗
Via Chartmill
News headline image
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Legend Biotech Corporation - American Depositary Shares publicly traded?
Yes, Legend Biotech Corporation - American Depositary Shares is publicly traded.
What exchange does Legend Biotech Corporation - American Depositary Shares trade on?
Legend Biotech Corporation - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Legend Biotech Corporation - American Depositary Shares?
The ticker symbol for Legend Biotech Corporation - American Depositary Shares is LEGN on the Nasdaq Stock Market
What is the current price of Legend Biotech Corporation - American Depositary Shares?
The current price of Legend Biotech Corporation - American Depositary Shares is 21.90
When was Legend Biotech Corporation - American Depositary Shares last traded?
The last trade of Legend Biotech Corporation - American Depositary Shares was at 01/07/26 09:57 AM ET
What is the market capitalization of Legend Biotech Corporation - American Depositary Shares?
The market capitalization of Legend Biotech Corporation - American Depositary Shares is 6.76B
How many shares of Legend Biotech Corporation - American Depositary Shares are outstanding?
Legend Biotech Corporation - American Depositary Shares has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.